| β* | Frequency †|
---|---|---|
Demographics | Â | Â |
Age <50 | –0.47 |  |
Age >70 | 0.86 | Â |
Heart disease | Â | Â |
History of MI | 0.52 | Â |
LVEF <40% | 0.31 | Â |
Killip class II–IV | 0.54 |  |
Beta-blocker use | –0.53 |  |
Comorbidity | Â | Â |
Diabetes | 0.47 | Â |
General health | Â | Â |
BMI <20 | 0.20 | Â |
Selected interactions | Â | Â |
Killip class * beta-blocker use | 0.26 | 95/100 |
Male sex * LVEF <40% | 0.14 | 68/100 |
Male sex * age <50 | –0.18 | 64/100 |
Male sex * depression high‡ | 0.13 | 64/100 |
Male sex * hyperlipidaemia | –0.17 | 61/100 |
Diabetes * beta-blocker use | 0.10 | 36/100 |
Killip class * hyperlipidaemia | 0.10 | 34/100 |